Female Infertility
Also known as: Hydrosalpinx
Methodology & AI Transparency ⓘ
Female Infertility Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Infertility means not being able to get pregnant after at least one year of trying (or 6 months if the woman is over age 35).
- 2 Real-world patient consensus: Diagnostic registry N97.9: Female Infertility is managed within Fertility & Pregnancy (aka Hydrosalpinx).
- 3 Typical cash cost range: Primary evaluation for Female Infertility incorporates semen analysis [Female Infertility N97.9] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Female Infertility: Prenatal TSH, Ferritin in Female Infertility (N97.9: & Glucose Screen) (Trimester-specific clinical range (N97.9)) and Anti-Mullerian Hormone (AMH) in Female Infertility (N97.9: & Day-3 FSH).
Ask our AI Specialists anything about Female Infertility
What Is Female Infertility?
Infertility means not being able to get pregnant after at least one year of trying (or 6 months if the woman is over age 35). If a woman keeps having miscarriages , it is also called infertility. Female infertility can result from age, physical problems, hormone problems, and lifestyle or environmental factors. Most cases of infertility in women result from problems with producing eggs. In primary ovarian insufficiency , the ovaries stop functioning before natural menopause. In polycystic ovary syndrome (PCOS), the ovaries may not release an egg regularly or they may not release a healthy egg. About a third of the time, infertility is because of a problem with the woman.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in fertility & pregnancy, Female Infertility (N97.9) involves micronutrient demand surge [Female Infertility N97.9]. Cross-referenced with NIH MeSH (Infertility, Female), progression correlates with shifts in Prenatal TSH, Ferritin in Female Infertility (N97.9: & Glucose Screen) (Trimester-specific clinical range (N97.9)).
Common Symptoms & Clinical Signs
- • Presentation of Female Infertility (N97.9): irregular luteal phase in Female Infertility (N97.9: timing, anovulatory cycles,)
- • Secondary Female Infertility clinical sign: gestational blood pressure in Female Infertility (N97.9: elevation, sudden hand/facial)
- • Symptom flares in Female Infertility correlating with Prenatal TSH, Ferritin in Female Infertility (N97.9: & Glucose Screen) deviation outside Trimester-specific clinical range (N97.9)
- • Functional fertility & pregnancy impact requiring semen analysis [Female Infertility N97.9] evaluation (N97.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Female Infertility Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N97.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Fertility, Pregnancy & Postpartum Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Prenatal TSH, Ferritin in Female Infertility (N97.9: & Glucose Screen) | Trimester-specific clinical range (N97.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Anti-Mullerian Hormone (AMH) in Female Infertility (N97.9: & Day-3 FSH) | Age-contextual ovarian reserve (N97.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Maternal Blood Pressure in Female Infertility (N97.9: & Urine Protein) | BP < 120/80 mmHg; negative proteinuria (N97.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Female Infertility
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Glydo- Lidocaine Hydrochloride Jelly Glydo- Lidocaine Hydrochloride Jelly Generic • RxCUI 1011852 | Amide Local Anesthetic | 86% | $0.5046 | $ 28.94 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Female Infertility)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Interventions for female pattern hair: What a 2,349-Participant Study Found Further direct comparison studies of minoxidil 5% applied once a day, which could improve staying on track with medication when compared to minoxidil 2% twice daily, are still required. The Cochrane database of systematic reviews • 2012-05-16 • Meta-Analysis | N = 2,349 | 99/100 | PMID 22592723 ↗ |
| New Insights on Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily: What a 551-Participant Study Found Conclusions: Tretinoin 0.05% lotion was significantly more effective than vehicle in achieving treatment success and reducing inflammatory and noninflammatory lesions in adult females with moderate acne, with notable... Journal of drugs in dermatology : JDD • 2019-11-01 • Randomized Controlled Trial | N = 551 | 93/100 | PMID 31741360 ↗ |
| New Insights on Benefits and safety of Ponesimod Compared with Teriflunomide in Female Patients: What a 363-Participant Study Found Conclusions: Analyses demonstrate the real-world benefits and safety of ponesimod, versus active comparator, for women with relapsing MS, supporting data-informed decision-making for women with MS. Journal of women's health (2002) • 2024-04-15 • Phase III Randomized Trial | N = 363 | 93/100 | PMID 38301149 ↗ |
| New Insights on A randomized, compared against a dummy pill (placebo) trial of 5% and 2%: What a 381-Participant Study Found In this 48-week study of 381 women with female pattern hair loss, 5% applied to the skin minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus... Journal of the American Academy of Dermatology • 2004-04-15 • Randomized Controlled Trial | N = 381 | 93/100 | PMID 15034503 ↗ |
| New Insights on Modeling and simulation of sexual activity daily diary data of patients with: What a 614-Participant Study Found A modeling and simulation framework to support drug development in FSAD was developed. Pharmaceutical research • 2006-08-15 • Randomized Controlled Trial | N = 614 | 93/100 | PMID 16841199 ↗ |
Female Infertility Patient Community & “People Like Me” Threads
Filter Female Infertility community threads and patient logs by age, biological sex, dosage, and treatment duration.